In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.

中文翻译：

---

肿瘤免疫逃避心脏的突变KRAS。

在寻找用于治疗癌症的治疗性组合中，致癌驱动途径的靶向抑制剂与免疫疗法的配对已被大大忽略。在自然界，佳能等。（2019）描述了新型KRAS-G12C抑制剂AMG 510如何结合免疫检查点封锁来增强免疫排斥反应。